iSIA Bio-technology
Shanghai, China· Est.
A biotech innovator developing next-generation antibody and cell therapies for oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A biotech innovator developing next-generation antibody and cell therapies for oncology.
Oncology
Technology Platform
Proprietary platforms for designing next-generation antibodies (bispecifics, ADCs) and engineering allogeneic CAR-T and CAR-NK cell therapies.
Opportunities
Potential to address the large unmet need in solid tumor immunotherapy with a scalable, off-the-shelf cell therapy product.
Risk Factors
High technical and clinical risk associated with pioneering allogeneic cell therapies, particularly for solid tumors.
Competitive Landscape
Operates in the highly competitive and capital-intensive field of cell therapy, racing against numerous peers to bring allogeneic products to market.